PT920873E - Solucoes estabilizadas de teriparatida - Google Patents

Solucoes estabilizadas de teriparatida

Info

Publication number
PT920873E
PT920873E PT98123225T PT98123225T PT920873E PT 920873 E PT920873 E PT 920873E PT 98123225 T PT98123225 T PT 98123225T PT 98123225 T PT98123225 T PT 98123225T PT 920873 E PT920873 E PT 920873E
Authority
PT
Portugal
Prior art keywords
stabilized solution
solution solutions
solutions
stabilized
solution
Prior art date
Application number
PT98123225T
Other languages
English (en)
Inventor
Chin-Ming Chang
Henry A Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT920873(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT920873E publication Critical patent/PT920873E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
PT98123225T 1997-12-09 1998-12-07 Solucoes estabilizadas de teriparatida PT920873E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
PT920873E true PT920873E (pt) 2004-06-30

Family

ID=22086574

Family Applications (2)

Application Number Title Priority Date Filing Date
PT3104219T PT1417972E (pt) 1997-12-09 1998-12-07 Soluções estabilizadas de teriparatida
PT98123225T PT920873E (pt) 1997-12-09 1998-12-07 Solucoes estabilizadas de teriparatida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT3104219T PT1417972E (pt) 1997-12-09 1998-12-07 Soluções estabilizadas de teriparatida

Country Status (32)

Country Link
EP (2) EP1417972B2 (pt)
JP (1) JP4405666B2 (pt)
KR (1) KR100482703B1 (pt)
CN (1) CN1198644C (pt)
AR (1) AR018526A1 (pt)
AT (1) ATE260113T1 (pt)
AU (1) AU759726B2 (pt)
BR (1) BR9813463A (pt)
CA (1) CA2314313C (pt)
CY (1) CY1114000T1 (pt)
CZ (1) CZ302401B6 (pt)
DE (1) DE69821872T2 (pt)
DK (2) DK0920873T3 (pt)
EA (1) EA004761B1 (pt)
EG (1) EG23675A (pt)
ES (2) ES2215268T3 (pt)
HK (1) HK1021798A1 (pt)
HU (1) HU230784B1 (pt)
ID (1) ID27741A (pt)
IL (1) IL136662A (pt)
MY (1) MY120063A (pt)
NO (1) NO327302B1 (pt)
NZ (1) NZ505222A (pt)
PE (1) PE20000001A1 (pt)
PL (1) PL194268B1 (pt)
PT (2) PT1417972E (pt)
SK (1) SK288203B6 (pt)
TR (1) TR200002134T2 (pt)
TW (1) TW570811B (pt)
UA (1) UA72884C2 (pt)
WO (1) WO1999029337A1 (pt)
ZA (1) ZA9811127B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912243A (pt) * 1998-07-23 2001-10-16 Lilly Co Eli Formulações de fsh e variantes de fsh, produtos e processos
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
IL147731A0 (en) * 2000-05-19 2002-08-14 Bionebraska Inc Peptide pharmaceutical formulations
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
AU2002363412A1 (en) * 2001-11-05 2003-05-19 Eli Lilly And Company Method for improving stability of a bone-connecting implant
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
RS57872B1 (sr) 2003-04-02 2018-12-31 Ares Trading Sa Tečne farmaceutske formulacije fsh i lh zajedno sa nejonskim surfaktantom
CA2526099C (en) 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
RU2421238C2 (ru) 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP2457580A1 (en) * 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
AU2006315132A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
JP2010523710A (ja) * 2007-04-12 2010-07-15 インフィニティ・ディスカバリー・インコーポレイテッド ヒドロキノンアンサマイシン製剤
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
MX2009013886A (es) 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
JP5583680B2 (ja) 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN103893746A (zh) * 2009-09-09 2014-07-02 旭化成制药株式会社 含有pth的骨质疏松症治疗/预防剂
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP3415139B8 (en) 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
MX2021005561A (es) 2015-04-29 2022-07-01 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
KR102524255B1 (ko) 2016-03-01 2023-04-20 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
ES2943720T3 (es) 2016-09-29 2023-06-15 Ascendis Pharma Bone Diseases As Compuestos de PTH con bajas relaciones de pico a valle
HRP20231079T1 (hr) 2016-09-29 2023-12-22 Ascendis Pharma Bone Diseases A/S Režim za doziranje pth spoja s kontroliranim oslobađanjem
CN110191707A (zh) 2017-01-05 2019-08-30 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR20200044016A (ko) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CA3167644A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 Ｎ－ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
WO2020165087A1 (en) * 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
WO2021195877A1 (en) * 2020-03-30 2021-10-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 ｈ―ＰＴＨ（１―３４）凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) † 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
JP3717925B2 (ja) 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
DE69821872D1 (de) 2004-04-01
EP1417972B1 (en) 2013-04-10
PL340902A1 (en) 2001-03-12
NO20002945D0 (no) 2000-06-08
ZA9811127B (en) 2000-07-11
CA2314313A1 (en) 1999-06-17
EP1417972A1 (en) 2004-05-12
DK1417972T4 (en) 2018-10-22
EP0920873A2 (en) 1999-06-09
ES2405994T3 (es) 2013-06-04
JP2001525372A (ja) 2001-12-11
CZ302401B6 (cs) 2011-05-04
EG23675A (en) 2007-04-15
EA200000629A1 (ru) 2000-12-25
CA2314313C (en) 2005-02-08
CZ20002115A3 (en) 2001-05-16
HUP0004447A2 (hu) 2001-04-28
NO20002945L (no) 2000-07-07
AU759726B2 (en) 2003-04-17
PL194268B1 (pl) 2007-05-31
ATE260113T1 (de) 2004-03-15
JP4405666B2 (ja) 2010-01-27
DK1417972T3 (da) 2013-05-13
DK0920873T3 (da) 2004-06-28
MY120063A (en) 2005-08-30
PT1417972E (pt) 2013-05-24
PE20000001A1 (es) 2000-01-17
WO1999029337A1 (en) 1999-06-17
CN1281370A (zh) 2001-01-24
SK15322000A3 (sk) 2001-05-10
TR200002134T2 (tr) 2000-11-21
EP1417972B2 (en) 2018-08-22
EA004761B1 (ru) 2004-08-26
HK1021798A1 (en) 2000-07-07
CN1198644C (zh) 2005-04-27
CY1114000T1 (el) 2016-07-27
EP0920873A3 (en) 1999-08-04
HU230784B1 (en) 2018-05-02
IL136662A (en) 2004-09-27
DE69821872T2 (de) 2005-01-05
KR20010032881A (ko) 2001-04-25
SK288203B6 (sk) 2014-07-02
ES2215268T3 (es) 2004-10-01
IL136662A0 (en) 2001-06-14
ID27741A (id) 2001-04-26
NZ505222A (en) 2003-05-30
AR018526A1 (es) 2001-11-28
TW570811B (en) 2004-01-11
AU1717799A (en) 2005-05-16
BR9813463A (pt) 2000-10-10
ES2405994T5 (es) 2019-01-30
HUP0004447A3 (en) 2003-06-30
EP0920873B1 (en) 2004-02-25
UA72884C2 (uk) 2005-05-16
NO327302B1 (no) 2009-06-02
KR100482703B1 (ko) 2005-04-14

Similar Documents

Publication Publication Date Title
PT920873E (pt) Solucoes estabilizadas de teriparatida
DE69826749D1 (de) Stabilisierte Persäurelösungen
MX208461B (es) Polisacaridos de termofraguado
DE69839157D1 (de) Fullurene enthaltendes katherdersystem
ID24529A (id) Turunan-turunan 9-oksima eritromisin
NO982004D0 (no) Dekstranfremstilling
NO995064L (no) Seleksjonsmarkör
DE69815673T2 (de) Stabilisierte hydroxylaminlösungen
NO20002482D0 (no) Pyridylpyrrolderivater
ATA111897A (de) Kimme
ATA112597A (de) Snowboard - bindung
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
FI972138A0 (fi) Returtraog i bestrykningsanordning
FR2770103B1 (fr) Bigoudi perfectionne
ATA86797A (de) Verschleissschuh
ATA46498A (de) Kunststoffgleitbahn
PT9429T (pt) Gaita de foles
PT9496T (pt) Enfuste aperfeicoado
BR7702750U (pt) Disposição em conjunto de grade-suporte
BR9701099A (pt) Acertrol i
FI972997A0 (fi) Anordning i en sugsamlarvagn
FI971651A0 (fi) Spaormaskin i en elmaskin
FI972640A0 (fi) Gapformare i en pappersmaskin/kartongmaskin
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog
FI971123A0 (fi) Foervarings- och transportredskap i synnerhet foer pappersprodukter